Table 2.
Clinicopathological parameters of patients by isoform PR status
| Clinopathological parameter | PRA-H No. (%) | PRB-H No. (%) | P |
|---|---|---|---|
| PR+ patients | 116/180 (64.4) |
64/180 (35.6) |
<.001* |
| Age, mean ± SD, y | 63 ±14.1 | 60 ± 12.9 | .21† |
| Tumor size, cm | <.001‡ | ||
| Nonpalpable | 1/99 (1.0) | 0/55 (0.0) | |
| <2 | 48/99 (48.5) | 9/55 (16.4) | |
| 2–5 | 42/99 (42.4) | 34/55 (61.8) | |
| >5 | 8/99 (8.1) | 12/55 (21.8) | |
| Positive nodes | 49/92 (53.3) | 19/37 (51.4) | .84* |
| Positive metastases | 4/66 (6.1) | 1/38 (2.6) | .65‡ |
| Histologic type | .51* | ||
| IC NST | 91/112 (81.3) | 47/58 (81.0) | |
| ILC | 14/112 (12.5) | 5/58 (8.6) | |
| SS | 7/112 (6.3) | 6/58 (10.3) | |
| Histologic grade | .01§ | ||
| I | 9/88 (10.2) | 1/46 (2.2) | |
| II | 35/88 (39.7) | 12/46 (26.0) | |
| III | 44/88 (50.0) | 33/46 (71.7) | |
| PR status | .004§ | ||
| 0 | 0/108 (0.0) | 0/52 (0.0) | |
| 1–25 | 22/108 (20.4) | 18/52 (34.6) | |
| 26–50 | 11/108 (10.2) | 13/52 (25.0) | |
| 51–75 | 22/108 (20.4) | 4/52 (7.7) | |
| 76–100 | 53/108 (49.1) | 17/52 (32.7) | |
| ERα status | .23§ | ||
| 0 | 1/107 (0.9) | 1/52 (1.9) | |
| 1–25 | 12/107 (11.2) | 7/52 (13.5) | |
| 26–50 | 4/107 (3.7) | 4/52 (7.7) | |
| 51–75 | 19/107 (17.8) | 11/52 (21.2) | |
| 76–100 | 71/107 (66.4) | 29/52 (55.8) | |
| HER2-positive | 6/102 (5.9) | 8/50 (16.0) | .04* |
| Ki-67 status (<14%) | 43/58 (74.1) | 7/23 (30.4) | <.001* |
*
P value was calculated using a two-sided chi-square test. ERα = estrogen receptor alpha; IC NST = invasive carcinoma of no special type; ILC = invasive lobular carcinoma; PR = progesterone receptor; PRA-H = tumors with higher levels of isoform A of progesterone receptor (PR-A) than isoform B (PR-B); PRB-H = tumors with higher levels of PR-B than PR-A; SS = special subtype.
†
P value was calculated using a two-sided Student’s t test
‡
P value was calculated using a two-sided Fisher exact test.
§
P value was calculated using a two-sided Cochran-Armitage trend test.